Pharmaceuticals
Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region
ABU DHABI, UAE, June 25, 2026 /PRNewswire/ -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global pharmaceutical leader MSD (Merck & Co., Inc., Rahway, New...
2026-06-25 03:15
366
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan ...
2026-06-24 18:19
753
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...
2026-06-24 16:08
626
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...
2026-06-24 15:07
879
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...
2026-06-24 11:53
585
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...
2026-06-23 21:12
515
Fair Play Menarini International Award
Diego Milito and Emilio Butragueño among the winners of the 30th edition FLORENCE, Italy, June 23, 2026 /PRNewswire/ -- The list of winners of the 30th Fair Play Menarini International Award, scheduled forJuly 2 in Florence, continues to include great legends of world sport. Among the champions w...
2026-06-23 18:29
551
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
* Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug ...
2026-06-23 18:10
825
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
1952
DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partner...
2026-06-23 07:47
2055
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
2428
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
* European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free sur...
2026-06-22 21:14
1059
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:33
1097
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment ...
2026-06-22 14:00
654
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
2026-06-22 08:30
1006
Pope Leo XIV embraces paediatric patients at CNAO in Pavia
PAVIA, Italy, June 20, 2026 /PRNewswire/ -- The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV's pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dial...
2026-06-20 23:50
1878
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial
SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 cl...
2026-06-18 10:00
3674
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is ev...
2026-06-17 16:06
2776
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. Three leading scientists in the field of cellular immunotherapy, Drs. Steven A. Rosenberg, Michel Sadelain, an...
2026-06-16 20:30
730
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
BANGKOK, June 16, 2026 /PRNewswire/ -- Informa Markets joins forces with Thailand's Department of Health Service Support (DHSS) to unveil International Healthcare Week 2026, a transformative regional healthcare platform that will elevate Thailand's position as a world-leading medical and wellness...
2026-06-16 12:24
2540
Week's Top Stories
Most Reposted
NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 302 media titles]
2026-06-19 11:12
Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 301 media titles]
2026-06-19 09:00
IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
Carro enters Australia with CarPlace acquisition to bring better, transparent car buying and selling experience to Australians
[Picked up by 295 media titles]
2026-06-18 10:00
Most Read
Resilience Actions, a Re Sustainability Initiative, Launches ECOHUB.IN to Power India's Climate and Circular Economy Innovation Ecosystem
2026-06-19 19:33
6112
LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026
2026-06-19 04:00
5383
